CADTH Canadian Drug Expert Committee recommendation: Latanoprostene bunod (Vyzulta -- Bausch Health, Canada Inc.) indication : for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension
The CADTH Canadian Drug Expert Committee (CDEC) recommends that latanoprostene bunod 0.24 mg/ml ophthalmic solution (Vyzulta) be reimbursed for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT) only if the following conditions are met...
| Corporate Authors: | , |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
July 2019, 2019
|
| Edition: | Version: 1.0 |
| Series: | CADTH common drug review
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The CADTH Canadian Drug Expert Committee (CDEC) recommends that latanoprostene bunod 0.24 mg/ml ophthalmic solution (Vyzulta) be reimbursed for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT) only if the following conditions are met : Conditions for Reimbursement : Initiation criteria 1. Patient must be ≥ 18 years 2. Patient must have a documented diagnosis of open-angle glaucoma or ocular hypertensionin one or both eyes. Pricing condition: The cost of treatment with LBN ophthalmic 0.024% solution should not exceed the drug plan cost of treatment with the least costly alternative prostaglandin analogue (PGA) or least costly beta-blocker reimbursed for the treatment of open-angle glaucoma or ocular hypertension |
|---|---|
| Physical Description: | 1 PDF file (7 pages) |